Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baitong decoction is a classical Traditional Chinese Medicine (TCM) formulation, originally documented in the *Shanghan Lun* (Treatise on Febrile Diseases), consisting of three primary herbal components: Aconiti Lateralis Radix Praeparata (Fuzi), Zingiberis Rhizoma (Ganjiang), and Allii Fistulosi Bulbus (Congbai). While traditionally indicated for 'Shaoyin' syndrome characterized by internal cold and diarrhea, modern pharmacological research has focused on its efficacy in treating ulcerative colitis (UC). The decoction functions as a multi-target anti-inflammatory agent that suppresses the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) and Stimulator of interferon genes (STING) signaling pathways. By inhibiting these pathways, Baitong decoction reduces the expression of pro-inflammatory cytokines such as TNF-α and IL-6, alleviates colonic tissue damage, and promotes the restoration of the intestinal mucosal barrier by increasing goblet cell numbers and mucus secretion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baitong decoction.